| 3D | Three-dimensional |
| ANOVA | Analysis Of Variance |
| Anti-CTLA4 | Anti-Cytotoxic T-Lymphocyte-associated Protein 4 |
| Anti-PD1 | Anti-Programmed Cell Death 1 |
| BMI | Body-Mass-Index |
| BOR | Best Overall Response |
| CB | Clinical Benefit |
| CR | Complete Response |
| CT | Computed Tomography |
| DFS | Disease Free Survival |
| FDG-PET/CT | 18F-2-Fluoro-2-desoxy-D-glucose Positron Emission Tomography/Computed Tomography |
| GCP | Good Clinical Practice |
| GE | General Electric |
| h | Hour |
| ICI | Immune Checkpoint Inhibitors |
| IQR | Interquartile Range |
| kV | Kilovolt |
| LDH | Lactate Dehydrogenase |
| mA | Milliampere |
| mg/dL | Milligram/Deciliter |
| mL | Milliliter |
| MSS | Melanoma Specific Survival |
| MTV | Metabolic Tumor Volume |
| OSEM | Ordered Subset Expectation Maximization |
| PD | Progressive Disease |
| PET | Positron Emission Tomography |
| PFS | Progression Free Survival |
| PR | Partial Response |
| S100 | Calcium-binding protein B |
| SD | Stable Disease |
| SUV | Standardized Uptake Value |
| TLG | Total Lesion Glycolysis |
| TOF | Time-of-Flight |
| TP | Time Point |
| VOI | Volume of Interest |